Solvay sells French site of Fournier
The Belgian Solvay group has put up for sale one of the French sites of Fournier, the pharmaceutical company it acquired two years ago. The site is based at Fontaine-les-Dijon. Unions are outraged and a group comprising the CFDT, CFTC, CGT FO and Unsa unions has said the sell-off process confirms what they argued at the outset, that Solvay "only seeks the commercial advantage of the anti-cholesterol drug Lipanthyl (fenofibrate)," developed by Fournier. Solvay is also in the process of selling Fournier's Synkem unit (Marketletter November 19).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze